Table 4

NY-ESO-1 expression by IHC (mAb ES121) and correlation with clinicopathological characteristics in EOC

Clinicopathological characteristicsNegativePositiveFocala++++++++++
All tumors, n (%)806252016183
(n = 142)(43%)(3.5%)(14%)(11.2%)(12.6%)(2.1%)
Tumor grade, n
 G1622
 G2611
 G3685952013183
FIGO stage, n
 IA211
 IC2
 IIB211
 IIC5
 IIIA1
 IIIB3
 IIIC585431814163
 IV76222
Histology (n)
 Serous605141712153
 Clear cell3211
 Endometroid411
 Mucinous4
 Undifferentiated2211
 Others761221
Dead of disease,b n (%)42 (52%)26 (42%)8 (40%)8 (50%)8 (44%)2 (67%)
  • a Focal, <5%; +, <25%; ++, >25–50%; +++, >50–75%; ++++, >75%.

  • b Median survival for patients with NY-ESO-1-positive and -negative tumors was 54 (CI, 26–83) and 45 (CI, 34–55) months, respectively (P = 0.30). Percentages were calculated by the proportion of patients dead of disease in relation to the total number of patients for each column.